Literature DB >> 4201649

Microtiter solid-phase radioimmunoassay for hepatitis B antigen.

R H Purcell, D C Wong, H J Alter, P V Holland.   

Abstract

A micro-solid-phase radioimmunoassay (micro-SPRIA) for hepatitis B antigen (HB Ag) was developed for use with microtiter serological equipment. Radiolabeled immunoglobulin G was prepared from human and animal sera containing hepatitis B antibody (HB Ab); it was not necessary to isolate specific HB Ab by immunochemical means. A micro-SPRIA prepared with guinea pig reagents was approximately as sensitive as the AusRIA radioimmunoassay, but, like the AusRIA test, yielded false positive results. A micro-SPRIA prepared with human reagents was slightly less sensitive but did not yield false positive results. These micro-SPRIA tests offer several advantages, including conservation of reagents, adaptability to other antigen-antibody systems, ease of performance (especially when testing large numbers of specimens), and economy.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4201649      PMCID: PMC379831          DOI: 10.1128/am.26.4.478-484.1973

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  17 in total

1.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

2.  Comparison of direct and indirect solid-phase microradioimmunoassays for the detection of viral antigens and antiviral antibody.

Authors:  J D Rosenthal; K Hayashi; A L Notkins
Journal:  Appl Microbiol       Date:  1973-04

3.  Specificity of the direct solid-phase radioimmunoassay for detection of hepatitis-B antigen.

Authors:  A M Prince; B Brotman; D Jass; H Ikram
Journal:  Lancet       Date:  1973-06-16       Impact factor: 79.321

4.  The heterogeneity of Australia antigen.

Authors:  G L Le Bouvier
Journal:  J Infect Dis       Date:  1971-06       Impact factor: 5.226

5.  Assay of Australia antigen and antibody employing double-antibody and solid-phase radioimmunoassay techniques and comparison with the passive hemagglutination methods.

Authors:  F B Hollinger; V Vorndam; G R Dreesman
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

6.  Frequency of antibody to hepatitis-associated antigen as measured by a new radioimmunoassay technique.

Authors:  J J Lander; H J Alter; R H Purcell
Journal:  J Immunol       Date:  1971-05       Impact factor: 5.422

7.  Preparation and characterization of complement-fixing hepatitis-associated antigen and antiserum.

Authors:  R H Purcell; J L Gerin; P V Holland; W L Cline; R M Chanock
Journal:  J Infect Dis       Date:  1970-02       Impact factor: 5.226

8.  Electroosmophoretic radioimmunoassay: application to hepatitis-associated antigen.

Authors:  R L Tilden; F H DeLand
Journal:  J Nucl Med       Date:  1972-08       Impact factor: 10.057

9.  Prevalence of hepatitis B virus antigen as revealed by direct radioimmune assay with 125 I-antibody.

Authors:  C M Ling; L R Overby
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

10.  Detection of Australia antigen by radioimmunoassay.

Authors:  R D Aach; J W Grisham; C W Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1971-05       Impact factor: 11.205

View more
  34 in total

1.  Comparison of electron microscopy, enzyme-linked immunosorbent assay, solid-phase radioimmunoassay, and indirect immunofluorescence for detection of human rotavirus antigen in faeces.

Authors:  C J Birch; N I Lehmann; A J Hawker; J A Marshall; I D Gust
Journal:  J Clin Pathol       Date:  1979-07       Impact factor: 3.411

Review 2.  Diagnosis of hepatitis via nanomaterial-based electrochemical, optical or piezoelectrical biosensors: a review on recent advancements.

Authors:  Soodabeh Hassanpour; Behzad Baradaran; Miguel de la Guardia; Amir Baghbanzadeh; Jafar Mosafer; Maryam Hejazi; Ahad Mokhtarzadeh; Mohammad Hasanzadeh
Journal:  Mikrochim Acta       Date:  2018-12-01       Impact factor: 5.833

3.  Enzyme-linked immunosorbent assay for detection of hepatitis A antigen in stool and antibody to hepatitis A antigen in sera: comparison with solid-phase radioimmunoassay, immune electron microscopy, and immune adherence hemagglutination assay.

Authors:  L R Mathiesen; S M Feinstone; D C Wong; P Skinhoej; R H Purcell
Journal:  J Clin Microbiol       Date:  1978-02       Impact factor: 5.948

4.  Detection of hepatitis A antigen by immunofluorescence.

Authors:  L R Mathiesen; S M Feinstone; R H Purcell; J A Wagner
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

5.  Solid-phase radioimmunoassay of rubella virus immunoglobulin G and immunoglobulin M antibodies.

Authors:  K O Kalimo; O H Meurman; P E Halonen; B R Ziola; M K Viljanen; K Granfors; P Toivanen
Journal:  J Clin Microbiol       Date:  1976-08       Impact factor: 5.948

6.  Screening for mumps immunity with the microtiter solid-phase radioimmunoassay.

Authors:  R Hernandez; M Just; A Bürgin-Wolff
Journal:  Infection       Date:  1976       Impact factor: 3.553

7.  Detection of hepatitis A virus and antibody by solid-phase radioimmunoassay and enzyme-linked immunosorbent assay with monoclonal antibodies.

Authors:  A G Coulepis; M F Veale; A MacGregor; M Kornitschuk; I D Gust
Journal:  J Clin Microbiol       Date:  1985-07       Impact factor: 5.948

8.  Solid-phase enzyme-linked immunosorbent assay for detection of hepatitis A virus.

Authors:  S A Locarnini; S M Garland; N I Lehmann; R C Pringle; I D Gust
Journal:  J Clin Microbiol       Date:  1978-09       Impact factor: 5.948

9.  Hepatitis B virus core antigen: synthesis in Escherichia coli and application in diagnosis.

Authors:  S Stahl; P MacKay; M Magazin; S A Bruce; K Murray
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

10.  Solid-phase enzyme-linked immunosorbent assay for detection of hepatitis A-specific immunoglobulin M.

Authors:  S A Locarnini; A G Coulepis; A M Stratton; J Kaldor; I D Gust
Journal:  J Clin Microbiol       Date:  1979-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.